Plasma Protease C1-inhibitor Market Size & Growth Forecast 2027–2036, By Segments (Dosage Form, Drug Class, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Plasma Protease C1-inhibitor Market size was estimated at USD 4.1 billion in 2026 and is projected to grow at a 9.31% CAGR from 2027 to 2036, surpassing USD 9.99 billion by 2036. The industry revenue for 2027 is assessed at USD 4.42 billion.
Get more details on this report
Request Free Sample ReportPlasma Protease C1-inhibitor Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 39.93% market share in 2026, supported by established hereditary angioedema treatment pathways, strong reimbursement, mature plasma infrastructure, and specialized rare-disease care.
- Asia Pacific is projected to expand at an 11.19% CAGR as improving rare-disease awareness, stronger diagnostics, expanding specialty healthcare access, and broader physician familiarity increase treatment adoption.
Segment Momentum
- Lyophilised dosage forms held a 60.64% share in 2026 because they provide product stability, practical storage, and dependable preservation of biologic activity for routine specialist treatment settings.
- Selective Bradykinin B2 Receptor Antagonists are the fastest-growing drug class as demand increases for targeted therapies that address acute episodes through a distinct mechanism of action.
Market Expansion Drivers
- Increasing diagnosis and awareness of hereditary angioedema expanding patient treatment base globally.
- Expanding regulatory approvals for novel formulations and administration routes improving patient access.
- Development of oral and subcutaneous therapies improving convenience and long-term disease management.
Leading Market Participants
- Top players in the plasma protease C1-inhibitor market include CSL Limited (Australia), Takeda Pharmaceutical Company Limited (Japan), Pharming Group N.V. (Netherlands), BioCryst Pharmaceuticals, Inc. (United States), KalVista Pharmaceuticals, Inc. (United States), Sanquin Blood Supply Foundation (Netherlands), CENTOGENE N.V. (Germany), Octapharma AG (Switzerland), Grifols, S.A. (Spain), Bio Products Laboratory Ltd. (United Kingdom).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.1 billion
- 2027 Estimated Market Size: USD 4.42 billion.
- Projected Market Size: USD 9.99 billion by 2036
- Growth Forecast: 9.31% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Lyphophlised (Dosage Form) | C1-inhibitors (Drug Class) | Hospital Pharmacies (Distribution Channel)
- Emerging Opportunity Segment: Injectables (Dosage Form) | Selective Bradykinin B2 Receptor Antagonist (Drug Class) | Online Pharmacies (Distribution Channel)
Market Growth Drivers and Industry Trends
Increasing diagnosis and awareness of hereditary angioedema expanding patient treatment base globally
Greater recognition of hereditary angioedema and improvements in diagnosis are contributing to the plasma protease C1-inhibitor market by enabling more affected individuals to receive appropriate disease management. Hereditary angioedema is associated with recurrent episodes of swelling that can affect different parts of the body, including the airways, making timely recognition and treatment particularly important. Increased awareness among healthcare professionals and patients can improve identification of previously undiagnosed cases, while advances in diagnostic testing can help distinguish the condition from other forms of edema. As more patients enter formal treatment pathways, demand for therapies that replace or supplement deficient C1-inhibitor activity becomes more relevant across acute and preventive care settings.
Expanding regulatory approvals for novel formulations and administration routes improving patient access
The plasma protease C1-inhibitor market is benefiting from broader regulatory acceptance of new formulations and delivery approaches that can address different treatment requirements for hereditary angioedema. Development of alternative administration routes can provide healthcare professionals and patients with greater flexibility in selecting therapies according to disease severity, treatment setting, and individual preferences. New formulations may also improve storage, administration, dosing practicality, or suitability for different stages of care, helping reduce barriers associated with conventional treatment approaches. As regulatory pathways support additional therapeutic options, clinicians can consider a broader range of C1-inhibitor-based interventions for patients requiring acute episode management or ongoing prophylactic treatment.
Development of oral and subcutaneous therapies improving convenience and long-term disease management
Greater emphasis on convenient administration is strengthening the plasma protease C1-inhibitor market as researchers and developers pursue therapies that can reduce the practical burden of long-term hereditary angioedema management. Subcutaneous administration can allow treatment to be incorporated more easily into outpatient or home-based care compared with approaches that require more complex clinical administration. Oral therapies, where clinically appropriate, could further improve accessibility and reduce treatment-related inconvenience for patients requiring ongoing disease control. These delivery innovations are particularly relevant for chronic disease management because treatment adherence can be influenced by administration complexity, patient comfort, and the ability to integrate therapy into everyday routines.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing diagnosis and awareness of hereditary angioedema expanding patient treatment base globally | 2.40% | High | North America, Europe | High | Near Term |
| Expanding regulatory approvals for novel formulations and administration routes improving patient access | 2.10% | High | North America, Europe, Asia Pacific | High | Near Term |
| Development of oral and subcutaneous therapies improving convenience and long-term disease management | 1.70% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the plasma protease C1-inhibitor market in 2026 at 39.93%, reflecting the region’s advanced healthcare infrastructure, established specialty-care ecosystem, and strong focus on rare disease diagnosis and treatment. Greater awareness of hereditary and acquired immune-related disorders supports demand for targeted therapies, while sophisticated healthcare delivery networks facilitate access to specialized treatments. Ongoing investment in biotechnology, clinical research, and innovative therapeutic approaches also strengthens the region’s market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region, supported by improving healthcare infrastructure, expanding access to specialized therapies, and increasing awareness of rare and hereditary disorders. Growth in diagnostic capabilities and greater emphasis on early disease identification are helping broaden the addressable patient population, while healthcare modernization and rising investment in advanced treatments are creating favorable conditions for adoption of plasma protease C1-inhibitor therapies.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Plasma Therapy StandardsGermany maintains strong clinical adoption of plasma-derived C1-inhibitor therapies through specialized immunology and hematology care. Healthcare institutions in Germany prioritize reliable plasma supply and evidence-based treatment protocols for rare disease management.
France 🇫🇷
Coordinated Specialty CareFrance emphasizes coordinated management of hereditary angioedema through specialist treatment networks and standardized clinical pathways. The plasma protease C1-inhibitor market in France is supported by careful integration of biologic therapies into hospital practice.
Italy 🇮🇹
Hospital Therapy AccessItaly relies on specialist hospitals and referral centers to deliver plasma protease C1-inhibitor therapies for eligible patients. Healthcare providers in Italy continue optimizing diagnosis and treatment access while maintaining high standards for plasma-derived products.
Japan 🇯🇵
Specialized Biologic AccessJapan supports plasma protease C1-inhibitor use through structured rare disease management and stringent biologics oversight. Pharmaceutical companies and healthcare providers in Japan focus on treatment quality, patient safety, and long-term therapeutic continuity.
South Korea 🇰🇷
Advanced Rare CareSouth Korea is strengthening access to plasma-derived therapies through specialized healthcare infrastructure and expanding rare disease awareness. The plasma protease C1-inhibitor market in South Korea benefits from increasing adoption of targeted biologic treatments.
United States 🇺🇸
Rare Disease TreatmentThe U.S. plasma protease C1-inhibitor market emphasizes expanded access to therapies for hereditary angioedema and related conditions. Healthcare providers in the U.S. continue integrating specialized treatment pathways supported by plasma collection and clinical research capabilities.
Segment Leadership and Growth Trends
Plasma Protease C1-inhibitor Market Share (%), by Dosage Form, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDosage Form Segment Analysis: Lyphophlised (Largest Segment) vs Injectables (Fastest-Growing Segment)
The lyophilized segment accounted for a 60.64% share of the plasma protease C1-inhibitor market in 2026, supported by the stability, storage advantages, and established handling characteristics offered by freeze-dried formulations. Lyophilization can help preserve biological activity during storage and facilitate distribution of protein-based therapeutics, making it valuable for products requiring controlled handling. Continued demand for reliable formulations for plasma-related therapeutic applications supports the segment's established position.
Injectables represent the fastest-growing dosage form as healthcare providers and patients increasingly favor administration formats that can enable direct and efficient delivery of therapeutic proteins. Advances in formulation and delivery technologies are supporting greater convenience and treatment flexibility, while increasing attention to timely management of hereditary and acquired conditions is expanding demand for injectable therapies. Improvements in self-administration and outpatient treatment models can further support adoption where appropriate.
Drug Class Segment Analysis: C1-inhibitors (Largest Segment) vs Selective Bradykinin B2 Receptor Antagonist (Fastest-Growing Segment)
C1-inhibitors held the largest share of the plasma protease C1-inhibitor market at 55.8% in 2026, reflecting their established therapeutic role in managing conditions associated with insufficient or dysfunctional C1-inhibitor activity. Their ability to address the underlying complement and contact-system imbalance makes them an important treatment option for hereditary angioedema and related indications. Continued clinical use and familiarity with replacement-based approaches are sustaining demand for this drug class.
Selective bradykinin B2 receptor antagonist is the fastest-growing drug class as treatment strategies increasingly focus on targeted modulation of the pathways responsible for swelling and inflammatory symptoms. Selective receptor activity can provide a more focused therapeutic approach, supporting interest in alternatives that directly address bradykinin-mediated effects. Ongoing advances in targeted therapies and demand for effective disease management are creating favorable conditions for broader adoption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Dosage Form | Lyphophlised, Injectables | Lyphophlised | Injectables |
| Drug Class | C1-inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist | C1-inhibitors | Selective Bradykinin B2 Receptor Antagonist |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Hospital Pharmacies | Online Pharmacies |
Competitive Landscape and Market Positioning
Major players in the plasma protease C1-inhibitor market:
1. CSL Limited (Australia)
2. Takeda Pharmaceutical Company Limited (Japan)
3. Pharming Group N.V. (Netherlands)
4. BioCryst Pharmaceuticals Inc. (United States)
5. KalVista Pharmaceuticals Inc. (United States)
6. Sanquin Blood Supply Foundation (Netherlands)
7. CENTOGENE N.V. (Germany)
8. Octapharma AG (Switzerland)
9. Grifols S.A. (Spain)
10. Bio Products Laboratory Ltd. (United Kingdom)
The plasma protease C1-inhibitor market is evolving through advancements in targeted therapeutic development for rare disease treatment. Continuous clinical innovation is enhancing treatment efficacy and patient response outcomes. The market is progressing through collaborative research efforts that accelerate biomedical innovation and therapeutic accessibility.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| CSL Limited (Australia) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Pharming Group N.V. (Netherlands) | |||||||
| BioCryst Pharmaceuticals Inc. (United States) | |||||||
| KalVista Pharmaceuticals Inc. (United States) | |||||||
| Sanquin Blood Supply Foundation (Netherlands) | |||||||
| CENTOGENE N.V. (Germany) | |||||||
| Octapharma AG (Switzerland) | |||||||
| Grifols S.A. (Spain) | |||||||
| Bio Products Laboratory Ltd. (United Kingdom). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| KalVista Pharmaceuticals | Jun-25 | KalVista Pharmaceuticals pursued regulatory advancement for sebetralstat, an oral plasma kallikrein inhibitor for hereditary angioedema, with FDA review and PDUFA milestone targeted for June 2025. The program includes global regulatory filings and lifecycle expansion initiatives, positioning the asset for potential commercialization across major markets. |
| CSL Behring | Jun-25 | CSL Behring received FDA approval for garadacimab (Andembry), a once-monthly subcutaneous prophylactic targeting activated Factor XII for hereditary angioedema prevention. The approval introduces a new treatment mechanism and strengthens CSL’s portfolio in long-acting prophylactic therapies, expanding competitive differentiation in the HAE treatment landscape. |
| BioCryst Pharmaceuticals | May-25 | BioCryst Pharmaceuticals reported Q1 2025 ORLADEYO sales of USD 134.2 million, representing significant year-over-year growth, and raised full-year revenue guidance to USD 580–600 million. The performance reflects continued commercial expansion of its oral prophylactic therapy in hereditary angioedema and strengthening market penetration across key geographies. |
| KalVista Pharmaceuticals | Mar-25 | KalVista Pharmaceuticals completed early enrollment expansion in the KONFIDENT-KID pediatric sebetralstat trial, increasing the cohort size to 36 participants. The study advancement supports pediatric development strategy and is intended to generate pivotal data for regulatory submissions and broader label expansion in hereditary angioedema treatment. |
| BioCryst Pharmaceuticals | Jun-24 | BioCryst Pharmaceuticals reported clinical data for berotralstat demonstrating significant reductions in monthly hereditary angioedema attack rates, including in patients with normal C1-inhibitor levels. The findings reinforce its efficacy profile as a once-daily oral prophylactic therapy and support broader clinical adoption across patient subgroups. |
| BioCryst Pharmaceuticals | May-23 | BioCryst Pharmaceuticals received marketing approval for ORLADEYO (berotralstat) in Chile for hereditary angioedema patients aged 12 and above. The approval expands geographic reach into Latin America, strengthening international commercialization and improving access to oral prophylactic treatment options in underserved markets. |
| Takeda Pharmaceutical Company | Feb-23 | Takeda Pharmaceutical Company received FDA approval for TAKHZYRO in pediatric patients aged 2 to under 12 years for prophylactic treatment of hereditary angioedema. The approval extends use into younger pediatric populations and strengthens its position in long-interval prophylactic therapies with improved dosing convenience. |
| Takeda Pharmaceutical Company | Apr-22 | Takeda Pharmaceutical Company secured FDA approval for CINRYZE for routine prophylaxis of hereditary angioedema attacks. The approval reinforces Takeda’s position in long-term prophylactic therapies and expands treatment options for patients requiring ongoing prevention of angioedema episodes across broader clinical populations. |
| CSL Behring | Sep-20 | CSL Behring obtained expanded indication approval for HAEGARDA for prevention of hereditary angioedema attacks in patients aged six years and older. The regulatory expansion broadened its pediatric reach and reinforced CSL’s position in plasma-derived C1-inhibitor therapies for long-term prophylactic treatment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Plasma Protease C1-inhibitor Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Setting | Hospital Inpatient, Hospital Outpatient, Specialty Clinics, Home Care |
| Patient Population | Hereditary Angioedema, Acquired Angioedema, Other C1-Inhibitor Deficiency Disorders |
| Payer Type | Commercial Insurance, Government Programs, Self-Pay |
Plasma Protease C1-inhibitor Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Rare Disease Treatment Access Assessment |
|
| Patient Journey and Treatment Gap Analysis |
|
| Plasma-Derived Therapy Supply Security Study |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of plasma protease C1-inhibitor?
How much is the plasma protease C1-inhibitor industry expected to grow by 2036?
How is improved diagnosis of hereditary angioedema expanding the treatment base in this market?
How are new formulations and administration routes improving market access and adoption?
Why are lyophilised dosage forms the largest segment in the plasma protease C1-inhibitor market?
Which drug class is growing fastest in the plasma protease C1-inhibitor market?
Why is North America the leading plasma protease C1-inhibitor market?
Why is Asia Pacific the fastest-growing plasma protease C1-inhibitor market?
Which companies dominate the plasma protease C1-inhibitor landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization